Peter Calder, MD
Ophthalmology · Wyomissing, PANPI 1043201106
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Alcon at 37.6% of the total. Reporting peaked in 2023 at $316 and has fallen 60.8% since, to $124 in 2025. That places this record below the midpoint for ophthalmology clinicians in PA, where the typical reported total is $1,202.
Across 53 payments — averaging $21.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$429
- AbbVie$181
- Glaukos Corporation$177
- Bausch & Lomb Americas Inc.$75
- Johnson & Johnson Surgical Vision, Inc.$50
- Oyster Point Pharma, Inc.$42
- plus $187 from 8 others
What the payments were for
- Food & beverage$1,141100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 23 | $429 |
| AbbVie(2 entities) | 7 | $181 |
| Glaukos Corporation | 5 | $177 |
| Bausch & Lomb Americas Inc. | 4 | $75 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $50 |
| Oyster Point Pharma, Inc. | 2 | $42 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $36 |
| Tarsus Pharmaceuticals, Inc. | 1 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
| Dompe US, Inc. | 1 | $25 |
| Shire North American Group Inc | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
| NEW World Medical,inc. | 1 | $13 |
How this compares
$1,141 in reported general payments places this provider in the 45th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 39 | $43,333 |
| LumiganBimatoprost | 82 | $27,289 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 77 | $14,476 |
| Cyclosporine | 11 | $11,456 |
| CombiganBrimonidine Tartrate/Timolol | 29 | $11,331 |
| VyzultaLatanoprostene Bunod | 26 | $7,432 |
| Latanoprost | 530 | $5,324 |
| Travoprost | 33 | $3,212 |
| Prednisolone Acetate | 88 | $2,610 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 88 | $2,172 |
| Loteprednol Etabonate | 15 | $2,134 |
| Timolol Maleate | 183 | $1,841 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 15 | $1,187 |
| Doxycycline Hyclate | 57 | $1,130 |
| Dexamethasone Sodium Phosphate | 26 | $1,130 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $181 | $81,953150 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $75 | $7,43226 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $36 | $2,13415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Wyomissing
- Christina OhnsmanWyomissing$138K
- Julia HallerPhiladelphia$1.5M
- Francis MahPittsburgh$1.1M
- Brandon AyresBala Cynwyd$929K
- David AlmeidaErie$734K
- Carl RegilloPlymouth Meeting$721K
- Robert NoeckerPittsburgh$632K
- Beeran MeghparaPhiladelphia$496K
- Michael KlufasPlymouth Meeting$393K
- Jonathan MyersPhiladelphia$359K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.